The new venture, called Onduo, aims to help people with diabetes better manage the disease by developing comprehensive solutions that combine devices, software, medicine and professional care to enable simple and intelligent disease management.
“As it will initially consist of connecting already existing products, we can expect the first innovations to arrive more quickly than if it was a pharmaceutical research programme starting from scratch,” Sanofi’s Head of Global Diabetes Franchise, Stefan Oelrich, told AFP.
Initially Onduo will focus on Type II diabetes; developing solutions that could help people make better decisions about their day to day health, ranging from improved medication management to improved habits and goals.
According to a statement issued by the companies, Onduo will leverage Verily’s experience in miniaturised electronics, analytics, and consumer software development, and Sanofi’s clinical expertise and experience in bringing innovative treatments to people living with diabetes.
“The integration of multiple interventions, such as data-driven patient support and devices in addition to treatment, can help improve outcomes, which is important from the perspective of patients, healthcare professionals and the overall healthcare system,” said Executive Vice President and General Manager, Diabetes & Cardiovascular at Sanofi, Peter Guenter.
Over time, the company plans to expand its focus to include the Type I diabetes and eventually to people at risk of developing diabetes with the goal of helping them better prevent the onset of the disease.
Verily was born out of Google’s X lab and has previously partnered with other pharmaceutical giants, including Novartis, to develop a smart contact lens that will help people with diabetes monitor their blood-sugar levels continuously and UK-based GlaxoSmithKline on a bioelectronic venture.